Moffitt Cancer Center & Research Institute
Welcome,         Profile    Billing    Logout  
 8 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Marie Catherine
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Hernandez, Carlos
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Czernecki, Brian
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Fazilova, Sevara
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Kruper, Laura
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Kassar, Onnah
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Ching-Tismal, Karen
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25

Download Options